B
12.66
0.13 (1.04%)
| Previous Close | 12.53 |
| Open | 12.56 |
| Volume | 317,177 |
| Avg. Volume (3M) | 489,130 |
| Market Cap | 548,890,752 |
| Price / Sales | 8.16 |
| Price / Book | 2.71 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | -101.62% |
| Operating Margin (TTM) | -105.69% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | 36.40% |
| Total Debt/Equity (MRQ) | 2.22% |
| Current Ratio (MRQ) | 15.88 |
| Operating Cash Flow (TTM) | -56.10 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Beta Bionics, Inc. | Bearish | - |
AIStockmoo Score
-0.8
| Analyst Consensus | 1.0 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.80 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 6.51% |
| % Held by Institutions | 98.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Lake Street, 136.97%) | Buy |
| Median | 21.00 (65.88%) | |
| Low | 17.00 (Baird, 34.28%) | Hold |
| Average | 22.67 (79.07%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 17.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 30 Jul 2025 | 17.00 (34.28%) | Hold | 16.76 |
| Truist Securities | 30 Jul 2025 | 21.00 (65.88%) | Buy | 16.76 |
| 16 Jun 2025 | 26.00 (105.37%) | Buy | 19.45 | |
| Lake Street | 12 Jun 2025 | 30.00 (136.97%) | Buy | 19.49 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEIDER STEPHEN | - | 16.47 | -10,000 | -163,963 |
| HOPMAN MARK | - | 15.88 | -16,158 | -256,589 |
| Aggregate Net Quantity | -26,158 | |||
| Aggregate Net Value ($) | -420,552 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.27 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEIDER STEPHEN | Officer | 22 Aug 2025 | Automatic sell (-) | 4,413 | 17.05 | 75,242 |
| FEIDER STEPHEN | Officer | 22 Aug 2025 | Option execute | 4,413 | - | - |
| HOPMAN MARK | Officer | 19 Aug 2025 | Automatic sell (-) | 16,158 | 15.88 | 256,589 |
| HOPMAN MARK | Officer | 19 Aug 2025 | Option execute | 16,158 | - | - |
| FEIDER STEPHEN | Officer | 19 Aug 2025 | Automatic sell (-) | 5,587 | 15.88 | 88,722 |
| FEIDER STEPHEN | Officer | 19 Aug 2025 | Option execute | 5,587 | - | - |
| Date | Type | Details |
|---|---|---|
| 21 Aug 2025 | Announcement | Beta Bionics Announces Participation at Upcoming Investor Conferences |
| 29 Jul 2025 | Announcement | Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance |
| 02 Jul 2025 | Announcement | Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025 |
| 19 Jun 2025 | Announcement | Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |